Better than Ozempic? The ‘King Kong’ of weight loss jabs is here, but there’s a catch…

A new weight loss drug promises to help people lose up to a quarter of their body weight. The only other treatment currently available that comes close to this effect is weight loss surgery. With 25.9 per cent of Britons currently obese and 37 per cent overweight, and with 250 chronic conditions directly related to obesity, from heart disease to cancer, this is being hailed as a huge breakthrough. 

Dubbed the “King Kong” of weight loss jabs, Mounjaro, the brand name for tirzepatide, is a weekly injection licensed to treat type 2 diabetes on the NHS. Trials have shown some users can lose up to 25 per cent of their body weight in 18 months – that’s 10 per cent more than other popular weight loss medication Wegovy over the same period.

That makes it the most powerful non-surgical option on the market for large-scale weight loss today. It’s been made available privately for weight loss patients who have a body mass index (BMI) of 30 or more, and those who have an index of 27-30 as well as a weight-related condition like heart disease or high blood pressure. It can also be prescribed on the NHS in certain circumstances. But does it sound too good to be true?


Related Articles

Bir cavab yazın

Sizin e-poçt ünvanınız dərc edilməyəcəkdir. Gərəkli sahələr * ilə işarələnmişdir

Back to top button